The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL
Open accessAbstract
BACKGROUND: Bupropion has been available in the United States since 1989. Initially a thrice-daily immediate-release formulation, a twice-daily sustained-release formulation followed in 1996, and, in August 2003, a once-daily extended-release formulation was introduced. On the 15th anniversary of its introduction, we undertook a review of the background/history, mechanism of action, formulations, and clinical profile of bupropion. DATA SOURCES: Major efficacy trials and other reports were obtained and reviewed from MEDLINE searches, review of abstracts from professional meetings, and the bupropion SR manufacturer's databases. Searches of English-language articles were conducted from June 2003 through August 2004. No time limit was specified in the searches, which were conducted using the search terms bupropion, bupropion SR, and bupropion XL. DATA SYNTHESIS: Bupropion inhibits the re-uptake of norepinephrine and dopamine neurotransmission without any significant direct effects on serotonin neurotransmission. Bupropion is an effective antidepressant with efficacy comparable to selective serotonin reuptake inhibitors and other antidepressants. It is well tolerated in short-and longer-term treatment. Headache, dry mouth, nausea, insomnia, constipation, and dizziness are the most common adverse events. Seizure and allergic reactions are medically important adverse events associated with bupropion and are reported rarely. Among all the newer antidepressants in the United States, bupropion appears to have among the lowest incidence of sexual dysfunction, weight gain, and somnolence. Although not U.S. Food and Drug Administration approved for these indications, bupropion has also been used as an adjunctive treatment to reverse antidepressant-induced sexual dysfunction and to augment anti-depressant efficacy in partial responders and non-responders to other agents. CONCLUSION: Bupropion has played and will continue to play an important role as a treatment for major depressive disorder in adults, as well as for other related disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., Muramoto, M. L., Daughton, D. M., Doan, K., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903043400903 · Cited by 1,585
Self-citationA Comparison of Sustained-Release Bupropion and Placebo for Smoking Cessation
Hurt, R. D., Sachs, D. P. L., Glover, E. D., Offord, K. P., Johnston, J. A., Dale, L. C., Khayrallah, M. A., Schroeder, D. R., Glover, P. N., Sullivan, C. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710233371703 · Cited by 1,261
Self-citationBupropion: a review of its mechanism of antidepressant activity.
Ascher, J. A., Cole, J. O., Colin, J. N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., & Richelson, E. (1995) · PubMed · Cited by 680
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Clayton, A. H., Pradko, J. F., Croft, H. A., Montano, C. B., Leadbetter, R. A., Bolden-Watson, C., Bass, K. I., Donahue, R. M. J., Jamerson, B. D., & Metz, A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0414 · Cited by 542
Self-citationFava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Self-citationStahl, S. M., Pradko, J., Haight, B. R., Modell, J. G., Rockett, C. B., & Learned-Coughlin, S. (2004) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v06n0403 · Cited by 495
Self-citationTashkin, D., Kanner, R., Bailey, W., Buist, S., Anderson, P., Nides, M., Gonzales, D., Dozier, G., Patel, M., & Jamerson, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04724-3 · Cited by 413
Hays, J. T., Hurt, R. D., Rigotti, N. A., Niaura, R., Gonzales, D., Durcan, M. J., Sachs, D. P. L., Wolter, T. D., Buist, A. S., Johnston, J. A., et al. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00011 · Cited by 343
Self-citationBupropion Hydrochloride in Attention Deficit Disorder with Hyperactivity
CONNERS, C. K., CASAT, C. D., GUALTIERI, C. T., WELLER, E., READER, M., REISS, A., WELLER, R. A., KHAYRALLAH, M., & ASCHER, J. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199610000-00018 · Cited by 342
Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial
Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research · doi:10.1038/oby.2002.86 · Cited by 315
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Self-citationA Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults
Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.282 · Cited by 272
A double-blind trial of bupropion versus desipramine for bipolar depression.
Sachs, G. S., Lafer, B., Stoll, A. L., Banov, M. D., Thibault, A., Tohen, M. F., & Rosenbaum, J. F. (1994) · PubMed · Cited by 272
Bupropion versus Methylphenidate in the Treatment of Attention-Deficit Hyperactivity Disorder
BARRICKMAN, L. L., PERRY, P. J., ALLEN, A. J., KUPERMAN, S., ARNDT, S. V., HERRMANN, K. J., & SCHUMACHER, E. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199505000-00017 · Cited by 254
Tonstad, S. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00003-4 · Cited by 246
Croft, H., Settle, E., Houser, T., Batey, S. R., Donahue, R. M. J., & Ascher, J. A. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88317-4 · Cited by 242
Clayton, A. H., Warnock, J. K., Kornstein, S. G., Pinkerton, R., Sheldon-Keller, A., & McGarvey, E. L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0110 · Cited by 222
Self-citationCooper, B. R., Hester, T. J., & Maxwell, R. A. (1980) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32266-4 · Cited by 213
Ferry, L., & Johnston, J. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10468.x · Cited by 209
Self-citationBupropion SR vs. Placebo for Weight Loss in Obese Patients with Depressive Symptoms
Jain, A. K., Kaplan, R. A., Gadde, K. M., Wadden, T. A., Allison, D. B., Brewer, E. R., Leadbetter, R. A., Richard, N., Haight, B., Jamerson, B. D., et al. (2002) · Obesity Research · doi:10.1038/oby.2002.142 · Cited by 205
Essential Psychopharmacology: Neuroscientific Basis and Practical Application
Ebert, M. H. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0510a · Cited by 184
Dunner, D. L., Zisook, S., Billow, A. A., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1998) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v59n0705 · Cited by 180 · cited 3×
“1%.(4) Certain factors may increase the risk of seizure; therefore, prior to the prescription of bupropion, patients should be screened for the presence of medical comorbidities, clinical situations, or concomitant medications that may lower seizure threshold.”
BackgroundMethodSelf-citationColeman, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80090-4 · Cited by 179
Gadde, K. M., Parker, C. B., Maner, L. G., Wagner, H. R., Logue, E. J., Drezner, M. K., & Krishnan, K. R. R. (2001) · Obesity Research · doi:10.1038/oby.2001.71 · Cited by 176
Bodkin, J. A., Lasser, R. A., Wines, J. D., Gardner, D. M., & Baldessarini, R. J. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0401 · Cited by 159
Bupropion Sustained Release Versus Paroxetine for the Treatment of Depression in the Elderly
Weihs, K. L., Settle, E. C., Batey, S. R., Houser, T. L., Donahue, R. M. J., & Ascher, J. A. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0309 · Cited by 150
Double-Blind Comparison of Bupropion Sustained Release and Sertraline in Depressed Outpatients
Kavoussi, R. J., Segraves, R. T., Hughes, A. R., Ascher, J. A., & Johnston, J. A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n1204 · Cited by 149
Self-citationFeinsod, M., Kreinin, B., Chistyakov, A. V., & Klein, E. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:2<73::aid-da4>3.0.co;2-6 · Cited by 140
Learned-Coughlin, S. M., Bergström, M., Savitcheva, I., Ascher, J., Schmith, V. D., & Långstrom, B. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01834-6 · Cited by 138
Bupropion treatment of attention-deficit hyperactivity disorder in adults
Wender, P. H., & Reimherr, F. W. (1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.8.1018 · Cited by 134
Coleman, C. C., Cunningham, L. A., Foster, V. J., Batey, S. R., Donahue, R. M. J., Houser, T. L., & Ascher, J. A. (1999) · Annals of Clinical Psychiatry · doi:10.1023/a:1022309428886 · Cited by 133
Studies of bupropion's mechanism of antidepressant activity.
Ferris, R. M., Cooper, B. R., & Maxwell, R. A. (1983) · PubMed · Cited by 129
Bupropion occupancy of the dopamine transporter is low during clinical treatment
Meyer, J. H., Goulding, V. S., Wilson, A. A., Hussey, D., Christensen, B. K., & Houle, S. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1166-3 · Cited by 122
Synaptic Effects of Antidepressants
RICHELSON, E. (1996) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199606002-00001 · Cited by 120 · cited 1×
“Bupropion is the only new generation antidepressant available in the United States with no appreciable serotonergic activity.(9,10,12,13) Bupropion appears to enhance monoaminergic neurotransmission via its effects on both the NE and DA transporters, with subsequent reuptake inhibition of these 2 neurotransmitters.”
BackgroundDouble-blind comparison of bupropion and fluoxetine in depressed outpatients.
Feighner, J. P., Gardner, E. A., Johnston, J. A., Batey, S. R., Khayrallah, M. A., Ascher, J. A., & Lineberry, C. G. (1991) · PubMed · Cited by 107
Self-citationComparison of Bupropion and Trazodone for the Treatment of Major Depression
Weisler, R. H., Johnston, J., Lineberry, C. G., Samara, B., Branconnier, R. J., & Billow, A. A. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199406000-00004 · Cited by 107
Self-citationLam, R. W. M., Hossie, H., Solomons, K., & Yatham, L. N. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0308 · Cited by 88
Johnston, J. A., Fiedler‐Kelly, J., Glover, E. D., Sachs, D. P. L., Grasela, T. H., & DeVeaugh-Geiss, J. (2001) · Nicotine & Tobacco Research · doi:10.1080/14622200110042852 · Cited by 86
Self-citationSelecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
Stahl, S. M. (1998) · PubMed · Cited by 85
Self-citationDeBattista, C., Solvason, H. B., Poirier, J., Kendrick, E., & Schatzberg, A. F. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200302000-00005 · Cited by 83
Substitution of an SSRI With Bupropion Sustained Release Following SSRI-Induced Sexual Dysfunction
Clayton, A. H., McGarvey, E. L., Abouesh, A., & Pinkerton, R. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0309 · Cited by 83
Self-citationSafety profile of sustained-release bupropion in depression: Results of three clinical trials
Settle, E. C., Stahl, S. M., Batey, S. R., Johnston, J. A., & Ascher, J. A. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)88301-0 · Cited by 83
Self-citationCroft, H. A., Houser, T. L., Jamerson, B. D., Leadbetter, R. A., Watson, C. B., Donahue, R. M. J., & Metz, A. L. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)85141-4 · Cited by 79
A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.
Lineberry, C. G., Ja, J., Rn, R., SAMARA, B., Feighner, J. P., Harto-Truax, N., Granacher, R. P., Weisler, R. H., Js, C., & Wf, B. (1990) · PubMed · Cited by 75
D, M. F. M., & Rankin, M. A. (2002) · PubMed · Cited by 74
Clinical pharmacology of bupropion and imipramine in elderly depressives.
Branconnier, R. J., Cole, J. O., Ghazvinian, S., Spera, K. F., Oxenkrug, G. F., & Bass, J. L. (1983) · PubMed · Cited by 66
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M. J., & Metz, A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01317-8 · Cited by 65
Double-Blind Comparison of Doxepin Versus Bupropion in Outpatients with a Major Depressive Disorder
Feighner, J. P., HENDRICKSON, G. G., Miller, L. L., & Stern, W. C. (1986) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198602000-00006 · Cited by 61
Rush, A. J. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00249-9 · Cited by 52
Self-citationA multicenter evaluation of bupropion versus placebo in hospitalized depressed patients.
Lf, F., Brodie, H. K. H., Garver, D., & Ww, Z. (1983) · PubMed · Cited by 49
Dong, J.-M., & Blier, P. (2001) · Psychopharmacology · doi:10.1007/s002130000665 · Cited by 48
A comparative study of bupropion and amitriptyline in depressed outpatients.
MENDELS, J., Amin, M. M., Chouinard, G., Cooper, A. J., Miles, J., Remick, R. A., Saxena, B., Secunda, S. K., & Singh, A. (1983) · PubMed · Cited by 43
Efficacy of bupropion in tricyclic-resistant or intolerant patients.
Stern, W. C., Harto-Truax, N., & Bauer, N. (1983) · PubMed · Cited by 41
Switching to Bupropion in Fluoxetine-Resistant Major Depressive Disorder
D, M. F. M., Papakostas, G., Petersen, T., Mahal, Y., Quitkin, F., Stewart, J., & McGrath, P. (2003) · Annals of Clinical Psychiatry · doi:10.1023/a:1023224525400 · Cited by 41
Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.
Wright, G., Galloway, L., Kim, J., Dalton, M., Miller, L. L., & Stern, W. C. (1985) · PubMed · Cited by 34
Dopamine transporter‐dependent induction of C‐Fos in HEK cells
Yatin, S. M., Miller, G. M., Norton, C., & Madras, B. K. (2002) · Synapse · doi:10.1002/syn.10084 · Cited by 27
The pharmacologic basis for therapeutic interest in bupropion.
Soroko, F. E., & Maxwell, R. A. (1983) · PubMed · Cited by 27
Bupropion in Tricyclic Antidepressant Nonresponders with Unipolar Major Depressive Disorder
Ferguson, J. M., Cunningham, L. A., Merideth, C., APTER, J. T., Feighner, J. P., Ionescu-Pioggia, M., Samara, B., Johnston, J. A., & Ascher, J. (1994) · Annals of Clinical Psychiatry · doi:10.3109/10401239409148997 · Cited by 25
Self-citationSafety and efficacy of bupropion and nortriptyline in outpatients with depression
Masco, H. L., Kiev, A., Holloman, L. C., et al. (1994) · Current Therapeutic Research · doi:10.1016/s0011-393x(05)80779-9 · Cited by 17
Cited by
The dopamine motive system: implications for drug and food addiction
Volkow, N. D., Wise, R. A., & Baler, R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.130 · Cited by 939
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 605
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations
Jefferson, J. W., Pradko, J. F., & Muir, K. T. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.11.011 · Cited by 408
Self-citationNutt, D., Demyttenaere, K., Janka, Z., Aarre, T., Bourin, M., Canonico, P. L., Carrasco, J. L., & Stahl, S. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106069938 · Cited by 366
Self-citationBupropion: pharmacology and therapeutic applications
Foley, K. F., DeSanty, K. P., & Kast, R. E. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1249 · Cited by 352
Metadata
- Authors
- Fava, M., Rush, A. J., Thase, M. E., Clayton, A., Stahl, S. M., Pradko, J. F., & Johnston, J. A.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2005-06-15
- Volume
- 7
- Issue
- 3
- Pages
- 106-13
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- OpenAlex
- W2082205780
- Cited by
- 258
- References
- 60
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.